Isis Acquires Symphony GenIsis, will Collaborate with Ortho-McNeil
Isis Pharmaceuticals, Inc. (Carlsbad, CA), has purchased Symphony GenIsis for $120 million.
Isis Pharmaceuticals, Inc. (Carlsbad, CA), has purchased Symphony GenIsis for $120 million. As part of the Symphony GenIsis purchase price, Isis paid Symphony Capital $80.4 million in cash and approximately 3.4 million shares of Isis stock, for an aggregate value of $39.6 million based on a 60-day average closing price before the date Isis exercised the repurchase.
Symphony GenIsis was formed in April 2006 by Symphony Capital Partners, L.P., and capitalized with $75 million to fund the development of three of Isis’ drugs. As part of that transaction, Isis licensed to Symphony GenIsis its cholesterol-lowering ISIS 301012 drug program, which targets apolipoprotein B-100, and two diabetes programs for the development of ISIS 325568 and ISIS 377131.
On September 13, 2007, Isis announced its metabolic disease-focused collaboration with Ortho-McNeil, Inc., to discover, develop, and commercialize up to four antisense drugs, which prompted the purchase of GenIsis. The collaboration includes licensing of two of the drugs previously held by Symphony GenIsis-ISIS 325568 and ISIS 377131-that target glucagon and glucocorticoid receptor.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
